CD274 and cervical cancer: Conversely, Naumann’s report on the CheckMate 358 trial explored the combination of nivolumab plus ipilimumab in two different dosing regimens, showing a clinical benefit across patients with advanced cervical cancer regardless of PD-L1 status or prior systemic therapies.